摘要
目的探讨氯吡格雷在冠心病患者介入治疗心血管不良事件预防中的临床效果。方法选取2015年2月至2017年2月本院收治的80例冠心病介入治疗患者,随机分为参考组和探究组,各40例。参考组采取阿司匹林治疗,探究组采用氯吡格雷,比较两组患者治疗干预效果。结果探究组临床疗效优于参考组(P<0.05);探究组血小板聚集率、活化部分凝血活酶时间优于参考组(P<0.05);用药前,两组患者血栓素B2水平比较差异无统计学意义,在用药6、12、24 h后,探究组血栓素B2水平明显低于参考组(P<0.05);探究组心血管不良事件发生率低于参考组(P<0.05)。结论冠心病介入治疗患者的治疗中应用氯吡格雷能够有效改善血小板聚集率、活化部分凝血活酶时间,提高临床疗效,预防心血管不良事件发生,值得临床推广使用。
Objective To investigate the clinical effect of clopidogrel in the prevention of cardiovascular adverse events in patients with coronary heart disease undergoing interventional therapy.Methods 80 patients with coronary artery disease who were treated in our hospital from February 2015 to February 2017 were selected,and were randomly divided into reference group and exploratory group,each with 40 cases.The patients in the reference group were treated with aspirin,and the patients in the exploratory group were treated with clopidogrel.The therapeutic intervention effects of the two groups were evaluated.Results Compared with the reference group,the clinical efficacy of the inquiry group was better than that of the reference group,and the platelet aggregation rate and activated partial thromboplastin time of the inquiry group were better than those of the reference group(P<0.05).There was no significant difference in the level of thromboxane B2 between the two groups before administration,after 6,12 and 24 hours of administration.The level of thromboxane B2 in the exploratory group was significantly lower than that in the reference group(P<0.05),and the incidence of cardiovascular adverse events in the exploratory group was lower than that in the reference group(P<0.05).Conclusion Clopidogrel can effectively improve platelet aggregation rate,activate partial thromboplastin time,improve clinical efficacy,prevent cardiovascular adverse events,and is suitable for popularization.
作者
吴资波
Wu zibo(Department of Cardiology,Yiyang People's Hospital,Yiyang,Hunan,413000,China)
出处
《当代医学》
2020年第36期95-97,共3页
Contemporary Medicine
关键词
冠心病
氯吡格雷
心血管不良事件
介入治疗血小板
凝血活酶
Coronary heart disease
Clopidogrel
Cardiovascular adverse events
Interventional platelet therapy
Thromboplastin
